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Introduction  
Postmenopause is one of the phases experienced by women 
due to the aging process. Postmenopausal women are characterized by 
cessation of menstruation and estrogen deficiency.
1 
An estrogen 
deficiency condition causes women to experience various health 
problems, one of such is osteoporosis.
2 
The disease is a condition of 
decreased bone density as a result of damage to the bone micro-
architecture, which may cause bone brittleness.
3 
Osteoporosis due to 
estrogen deficiency can be treated with hormone replacement therapy 
(HRT) or selective estrogen receptor modulators (SERMs).
4
 
Raloxifene is one of the SERMs, that have been shown to effectively 
reduce vertebral fracture in postmenopausal women.
5  
However, long-
term use of HRT or SERMs can cause various side effects, such as an 
increased risk of cardiovascular disorders, coronary events, venous 
thromboembolism, stroke, breast cancer, and dementia. These 
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A phytoestrogen is a group of compounds derived from plants that 
have a structure similar to estrogen. It can replace the function of 
estrogen in maintaining organ homeostasis, either by binding to the 
estrogen receptor (ER-dependent) or not (ER-independent). 
Phytoestrogen is easy to obtain and relatively has no side effects in 
application. Studies reported that phytoestrogen is effective to 
decrease complaints of diseases that arise due to estrogen 
deficiency,
8,9
 thus, it can be a potential alternative for the treatment of 
osteoporosis due to estrogen deficiency.
9
 Phytoestrogen can be found 
in several plants, such as Glycine max, Marsilea crenata, Pueraria 
montana, Humulus lupulus, Glycyrrhiza glabra, Ipomoea batatas, 
Rheum rhabarbarum, and Vitex agnus-castus.
10
 According to literature 
studies, there are at least 39 compounds that can be classified as 
phytoestrogen, including catechin, epicatechin, genistein, kaempferol, 
luteolin, myricetin, naringenin, and quercetin.
11-17 
 
In silico study is a type of drug discovery approach, in which the 
activity of a drug is determined by evaluating the interaction between 
a ligand (drug) and target (protein) using computer programs.
18 
The 
role of in silico studies in the discovery of new drugs is quite 
important as they help to visualize the mechanism of the drug against 
its target and optimize the compound form of the drug.
19 
Visuals from 
in silico studies are in the form of anchoring ligands or drug 
compounds to targets in the form of macromolecules to obtain 
physical and chemical properties from the most optimal to the worst.
20 
 
This research was performed to predict the antiosteoporosis activity of 
thirty-nine phytoestrogen compounds and a modern antiosteoporosis 
drug, raloxifene through an in silico study.  
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Osteoporosis is one of the health problems in postmenopausal women due to estrogen 
deficiency. Phytoestrogen compounds can be used as an alternative osteoporosis treatment 
because of their similarity in structure and activity to estrogen. This research was conducted to 
predict the antiosteoporosis activity of thirty-nine phytoestrogen compounds and raloxifene, a 
modern antiosteoporosis drug in silico. The first step of the study involved the analysis of 
physicochemical properties of thirty-nine compounds and raloxifene using the SwissADME web 
tool. Compounds that met the criteria of the physicochemical properties were then subjected to 
molecular docking using PyRx 0.8 software with the AutoDock Vina method. The results were 
analyzed using Biovia Discovery Studio Visualizer 2016 software to find one or more 
compounds that predicted ERβ agonists. Finally, a toxicity test using the pkCSM web tool on the 
predicted agonist compounds was conducted to determine the values of hepatoxicity, skin 
sensitization, and Ames toxicity. AdmetSAR2 web tool was also used to predict the LD50 class 
of toxicity. The results of this in silico study revealed that raloxifene and 23 compounds 
displayed agonist interaction toward ERβ, and two of these compounds, namely catechin and 
epicatechin, were predicted agonist to ERβ with binding values of -5.6 and -5.9 kcal/mol, 
respectively. These two compounds also showed the lowest toxicity. The finding from this 
research indicated that catechin and epicatechin are the most potent and non-toxic 
antiosteoporosis compounds among the 39 phytoestrogens. 
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Materials and Methods  
Materials 
The three-dimensional structure of the thirty-nine compounds and 
raloxifene was prepared using ChemDraw Ultra 12.0 software. The 
compounds were: apigenin, arbutin, baicalein, biochanin A, catechin, 
chalconaringenin, chrysin, coumestrol, cyanidin, daidzein, 
delphinidin, epicatechin, fisetin, formononetin, gallocatechin, 
genistein, glycitein, hesperidin, kaempferol, lariciresinol, luteolin, 
malvidin, matairesinol, medioresinol, morin, myricetin, naringenin, 
pelargonidin, peonidin, phloretin, phloridzin, puerarin, quercetin, 
resveratrol, rutin, secoisolariciresinol, sesamolin, syringaresinol, 
tangeretin, and one of SERMs, raloxifene. 
Besides the 39 tested compounds and raloxifene mentioned above, the 
structure of the native ligand, 17β-estradiol, and the protein (receptor) 
was also prepared. The three-dimensional crystal structure of the 
phosphorylated ERβ ligand-binding domain (ID 3OLL) was obtained 
from a protein data bank (www.rcsb.org). This protein was chosen 
because it has a native ligand in the form of estradiol. In addition, it is 




Analysis of physicochemical properties 
The first step was changing all the 39 phytoestrogen compounds as 
well as raloxifene to a simplified molecular-input line-entry system 
(SMILES) format from ChemDraw Ultra 12.0 software. Then, the 
SMILES format from each compound was copied and entered into the 
SwissADME web tool (http://www.swissadme.ch) to discover 
physicochemical properties based on its location in the Boiled-Egg 
diagram, Topological Polar Surface Area (TPSA) value, and 
Lipinski’s rule of five.
22,23
 Compounds that met physicochemical 
properties criteria were then subjected to molecular docking. 
 
Molecular docking 
The compounds that passed the selection of physicochemical analysis 
were prepared using Avogadro 1.0.1 software for geometry 
optimization to obtain a stable structure.
24,25
 The ERβ protein structure 
downloaded from PDB was then separated into native ligand and its 
protein using Biovia Discovery Studio Visualizer 2016 software.
26 
After that, an internal validation was done using ERβ protein re-
docking and native ligand 17β-estradiol to determine the validation of 
the AutoDock Vina method toward ERβ protein.
27,28
 Root Mean 
Square Deviation (RMSD) value of <2Å of the internal validation 
showed that the AutoDock Vina method is valid for molecular 
docking toward ERβ.
28,29
 The process of molecular docking using 
software PyRx 0.8 with the AutoDock Vina method on each 
compound toward ERβ protein (Figure 1), and the result was analyzed 
using Biovia Discovery Studio Visualizer 2016 software. The results 
of the molecular docking of each compound compared its similarity 





Figure 1: Grid box 17β-estradiol as native ligand 
 
Toxicity test 
This was conducted by inserting the compound’s SMILES format on 
the pkCSM web tool (http://biosig.unimelb.edu.au/pkcsm) to predict 
the values of Ames toxicity, skin sensitization, and hepatotoxicity. 
Meanwhile, the admetSAR2 web tool was used to predict the toxicity 
class of compounds’ lethal dose 50 (LD50). 
  
Results and Discussion 
Phytoestrogen compounds can be used as an alternative to treat health 
problems due to estrogen deficiency, such as osteoporosis.
8
 The use of 
alternative phytoestrogens becomes necessary due to the serious side 
effects of HRT or SERMs. Raloxifene is one example of SERMs and 
became the most widely studied compound within the second 
generation. It acts as an estrogen agonist in some tissues, while it 
functions as an estrogen antagonist in others. For example, when 
binding to the ER in osteoclast, osteoblast, and vascular endothelial 
cells, raloxifene can inhibit bone resorption mediated by the osteoclast 
and depress the serum cholesterol and low-density lipoprotein like the 
estrogen. While binding to the ER in mammary and endometria cells, 
raloxifene inhibits the hyperplasia of the two kinds of cells as the anti-
estrogen. Therefore, long-term consumption of raloxifene can cause 
serious effects due to its agonist properties in other tissues.
5,30
 In this 
research, an evaluation of the antiosteoporosis activity of 39 
phytoestrogen compounds was conducted through an in silico study. 
This kind of study can help to predict the simple structure of a 
compound that has potency as medicine, using computer software.
31 
The results of the analysis of physicochemical properties of the 
compounds through the Boiled-Egg diagram, Lipinski's Rule of Five, 
and TPSA value are represented in Figure 2 and Table 1. The Boiled-
Egg diagram and TPSA value indicate the ability of the compound to 
penetrate cell membranes. Compounds that can penetrate well are 
indicated by the TPSA value of ≤140 Å
2
, and the position of the 
compound in yellow and white spots in the Boiled-Egg diagram.
22,24
 
The white spot indicates a high probability of gastrointestinal 
absorption, and a yellow spot indicates a high probability of brain 
penetration. Boiled-Egg diagrams can show the bonding of 
compounds with P-glycoprotein (P-gp), namely P-gp “yes” or plus 
sign with blue color (P-gp substrate), and P-gp “no” or minus sign 
with red color (P-gp non-substrate).
22 
The other parameters from the 
physicochemical analysis are Lipinski’s rule of five, including 
molecular weight ≤500 g/mol, log P ≤5, HBD ≤ 5, HBA ≤ 10. 
Lipinski’s rule of five is stated with “Yes, 0 violation” in the 
SwissADME web tool. If a compound met the criteria of Lipinski’s 
rule of five, thus, that compound can be used orally and accepted by 
the body.
23
 The result of the physicochemical analysis showed that 32 
of the 39 phytoestrogen compounds and raloxifene met the parameter 
requirements. The result obtained from the molecular docking process 
was the bond affinity value of each compound that showed an affinity 




Figure 2: Physicochemical analysis of the phytoestrogen 
compounds through the Boiled-Egg diagram 
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Parameters of Lipinski's Rule of Five 














1 17β-estradiol 272.38 3.53 2 2 Yes 40.46 
2 Raloxifene 473.58 3.21 5 2 Yes 98.24 
3 Apigenin 270.24 2.11 5 3 Yes 90.90 
4 Arbutin 272.25 -0.77 7 5 Yes 119.61 
5 Baicalein 270.24 2.24 5 3 Yes 90.90 
6 Biochanin A 284.26 2.44 5 1 Yes 79.90 
7 Catechin 290.27 0.83 6 5 Yes 110.38 
8 Chalconaringenin 272.25 1.83 5 4 Yes 97.99 
9 Chrysin 254.24 2.55 4 2 Yes 70.67 
10 Coumestrol 268.22 2.46 5 2 Yes 83.81 
11 Cyanidin 287.24 0.56 6 5 Yes 114.29 
12 Daidzein 254.24 2.24 4 2 Yes 70.67 
13 Delphinidin 338.70 -0.79 7 6* No* 134.52 
14 Epicatechin 290.27 0.85 6 5 Yes 110.38 
15 Fisetin 286.24 1.55 6 4 Yes 111.13 
16 Formononetin 268.26 2.66 4 1 Yes 59.67 
17 Gallocatechin 306.27 0.52 7 6* No* 130.61 
18 Genistein 270.24 2.04 5 3 Yes 90.90 
19 Glycitein 284.26 2.30 5 2 Yes 79.90 
20 Hesperidin 610.56* -1.06 15* 8* No* 234.29* 
21 Kaempferol 286.24 1.58 6 4 Yes 111.13 
22 Lariciresinol 360.40 2.38 6 2 Yes 85.22 
23 Luteolin 286.24 1.73 6 4 Yes 111.13 
24 Malvidin 331.30 0.71 7 4 Yes 112.52 
25 Matairesinol 358.39 2.76 7 0 Yes 64.61 
26 Medioresinol 388.41 2.33 3 3 Yes 60.69 
27 Morin 302.24 1.2 7 5 Yes 131.36 
28 Myricetin 318.24 0.79 8 6* No* 151.59* 
29 Naringenin 272.25 1.84 5 3 Yes 86.99 
30 Pelargonidin 271.24 0.73 5 4 Yes 94.06 
31 Peonidin 301.27 0.76 6 4 Yes 103.29 
32 Phloretin 274.27 1.93 5 4 Yes 97.99 
33 Phloridzin 436.41 0.06 10 7* No* 177.14* 
34 Puerarin 416.38 0.23 9 6* No* 160.82* 
35 Quercetin 302.24 1.23 7 5 Yes 131.36 
36 Resveratrol 228.24 2.48 6 3 Yes 88.38 
37 Rutin 610.52* -1.51 16* 10* No* 269.43* 
38 Secoisolariciresinol 362.42 2.46 6 4 Yes 99.38 
39 Sesamolin 370.35 2.74 8 2 Yes 95.84 
40 Syringaresinol 418.44 2.33 7 2 Yes 86.61 
41 Tangeretin 372.37 3.02 7 0 Yes 76.36 
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The bond affinity value is used to describe bond energy in the 
compound-receptor complex. The more negative bond affinity value 




The result of the molecular docking process was analyzed using 
Biovia Discovery Studio Visualizer 2016 to discover which amino 
acid was bonded, types of amino acid bonds, and to map the 
pharmacophore distance of each compound when it binds to ERβ. 
Amino acids form a protein, so it is important to see the similarity of 
the results of the amino acid residues that are bound from the 
molecular docking process between proteins and ligands. Compounds 
that have agonist interaction are shown by binding to amino acids, His 
475, and Glu 305 or Arg 346. The relatively similar types of amino 
acids with the native ligand show the same interaction pattern, while 
compounds bind at least two of the same amino acids. However, the 
more similarities, the stronger the predictions of the similarity of 
activity.
34
 The type of amino acid bond shows the stability of the bond 
as well. A hydrogen bond is the most stable and strong bond.
35
 
Meanwhile, the pharmacophore distance is the minimum range that is 
required by the molecule to bind with the receptor and produce 
activity. A compound is called an ERβ agonist if it had a 
pharmacophore distance of about 11,126 Å. The similarity of the 
pharmacophore distance has a deviation of 1.0 from the native ligand; 
however, pharmacophore distance that slightly exceeds the tolerance 
limit can still be predicted to have similar activity if looking at the 
other parameters, for instance, amino acid bond.
26,36 
The result of the 
molecular docking also revealed that raloxifene and the 23 compounds 
showed agonist interaction to ERβ. The parameters of the native 
ligand and the results of molecular docking of compounds that were 
agonist can be seen in Figure 3 and Table 2. 
Toxicity tests were performed on compounds that have agonist 
interaction to ERβ, using pkCSM web tool to predict the values of 
hepatoxicity, skin sensitization, and Ames toxicity, whereas prediction 
of toxicity class of compound LD50 used admetSAR2 web tool. 
Hepatotoxicity is one of the kinds of toxicity used to identify 
compounds that are toxic to the liver.
37
 Skin sensitization is a 
hypersensitivity reaction caused by reactive chemicals that penetrate 
the stratum corneum layer of the skin.
38
 Ames toxicity is one of the 
methods used to discover the mutagenic and carcinogenic activity of 
several compounds.
39
 Toxicity tests are divided into various classes. 
The toxicity class of LD50 is used to predict the toxicity level of the 
compounds. There are four toxicity classes of LD50, namely class I, II, 
III, and IV. Class I contains the most toxic compound with a value of 
LD50 ≤50 mg/kg. Class II contains the quite toxic compound with a 
value of LD50 50 mg/kg, but less than 500 mg/kg. Class III contains 
the slightly toxic compound with a value of LD50 over 500 mg/kg, but 
less than 5000 mg/kg; and Class IV contains the safe compound (non-
toxic) with a value of LD50 >5000 mg/kg.
40,41 
 The result of the toxicity 
tests showed that raloxifene is quite toxic in Class II with LD50 of 400 
mg/kg, indicated "yes" to hepatoxicity and Ames toxicity. Meanwhile, 
of the 23 agonist compounds, there were 16 non-toxic phytoestrogens, 
where the values of hepatoxicity, skin sensitization, and Ames toxicity 
were shown by “no” on the pkCSM web tool. On the level of toxicity 
class, each compound was shown by grade I until IV on the 
admetSAR2 web tool (Table 3). Two of the 16 phytoestrogen 
compounds had the lowest toxicity. It was observed that the best 
toxicity class of LD50, such as catechin and epicatechin, which are in 
Class IV had a value of LD50 >5000 mg/kg and are considered safe 
(non-toxic).
40,41 
As a result of the physicochemical analysis, molecular 
docking, and toxicity tests in this research showed that raloxifene is an 
agonist ERβ and can be used to overcome osteoporosis in 
postmenopausal women. It has been reported in the literature that 
raloxifene acts as estrogen receptor (ER) agonist in bone. It prevents 
bone fracture by decreasing bone turnover and increasing bone 
mineral density.
30
 However, the results (Figure 4) obtained revealed 
that the pharmacophore distance and binding affinity values are far 
from the native ligand. In addition, one of the bound amino acid 
residues has a type of bond that is not strong enough. This indicates 
that some phytoestrogen compounds have molecular docking results 
that are more similar to native ligand than raloxifene. The molecular 
docking results (Figure 5 and Figure 6) of catechin and epicatechin 
were predicted to have the most potential to be developed into 
antiosteoporosis agent, not only because it has low toxicity, but also 
due to the similarity with 17β-estradiol. There are bonds between 
catechin and the amino acid residues His 475, Glu 305, and Arg 346, 
with a pharmacophore distance of 10,798 Å. As for epicatechin, there 
are bonds with amino acid residues His 475 and Glu 305, with a 
pharmacophore distance of 10,627 Å. These results indicated that both 
compounds are agonists to ERβ.
 
Phytoestrogen compounds that have agonist interaction with ERβ and 
are non-toxic can be predicted to have the ability to bind with ERβ. 
These compounds bind to ERβ to produce osteoblastogenesis 
cytokines such as TGF-β, IGF-1, and IGF-2. Production of these 
cytokines may cause the occurrence of the process of the osteoblast 
differentiation to become mature osteoblasts in the process of bone 
formation. In contrast, phytoestrogens that can bind to ERβ will 
reduce the production of osteoclastogenic cytokines including TNF-α, 
IL-1, and IL-6. If the production of cytokines decreased, it can inhibit 
the occurrence of osteoclast differentiation process and become 
mature osteoclast, resulting in the inhibition of the bone resorption 
process. On the other hand, the bonding phytoestrogen with ERβ can 




A                B 
 
Figure 3: Visualization of molecular docking of 17β-estradiol as native ligand against ERβ. A: 2D; B: 3D 
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Amino Acid (Type of Bond) 
Pharmacophore 
Distance (Å) 
1 17β-estradiol -10.2 His475(Hidrogen) Glu305(Hidrogen) Arg346(Hidrogen) 11.126 
2 Raloxifene 5.3 His475(unfavorable) Glu305(Hidrogen) 12.504 
3 Apigenin -6.3 His475(Hidrogen) Glu305(Hidrogen) Arg346(Hidrogen) 10.772 
4 Arbutin -6.2 His475(Hidrogen) Glu305(Hidrogen) 9.913 
5 Catechin -5.6 His475(Hidrogen) Glu305(Hidrogen) Arg346(Hidrogen) 10.798 
6 Chalconaringenin -7.1 His475(Hidrogen) Glu305(Hidrogen) 11.647 
7 Coumestrol -8.7 His475(Hidrogen) Glu305(Hidrogen) Arg346(Hidrogen) 11.293 
8 Cyanidin -7.4 His475(Hidrogen) Glu305(Hidrogen) 10.800 
9 Daidzein -8.2 His475(Hidrogen) Glu305(Hidrogen) Arg346(Hidrogen) 12.133 
10 Epicatechin -5.9 His475(Hidrogen) Glu305(Hidrogen) 10.627 
11 Fisetin -7.5 His475(Hidrogen) Glu305(Hidrogen) Arg346(Hidrogen) 10.727 
12 Genistein -8.2 His475(Hidrogen) Glu305(Hidrogen) Arg346(Hidrogen) 12.138 
13 Glycitein -5.0 His475(Hidrogen) Glu305(Hidrogen) Arg346(Hidrogen) 12.103 
14 Kaempferol -7.6 His475(Hidrogen) Glu305(Hidrogen) 10.871 
15 Lariciresinol -3.6 His475(Hidrogen) Glu305(Hidrogen) Arg346(Hidrogen) 12.162 
16 Luteolin -5.3 His475(Hidrogen) Glu305(Hidrogen) 9.660 
17 Malvidin -3.9 His475(Hidrogen) Arg346(Hidrogen) 10.750 
18 Morin -7.5 His475(Hidrogen) Glu305(Hidrogen) Arg346(Hidrogen) 10.923 
19 Naringenin -6.8 His475(Hidrogen) Glu305(Hidrogen) 10.708 
20 Pelargonidin -7.0 His475(Hidrogen) Glu305(Hidrogen) 10.237 
21 Peonidin -6.9 His475(Hidrogen) Arg346(Hidrogen) 10.742 
22 Phloretin -7.3 His475(Hidrogen) Glu305(Hidrogen) 11.361 
23 Quercetin -5.2 His475(Hidrogen) Glu305(Hidrogen) 10.590 
24 Resveratrol -6.6 His475(Hidrogen) Glu305(Hidrogen) Arg346(Hidrogen) 11.335 
25 Secoisolariciresinol -4.8 His475(Hidrogen) Glu305(Hidrogen) 10.183 
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Figure 6: Visualization of the molecular docking of epicatechin against ERβ. A: 2D; B: 3D 
 
This can inhibit the occurrence of bone loss.
42
 Catechin and 
epicatechin have potency as antiosteoporosis with ER-dependent 
mechanisms. It is indicated by agonist interactions of both compounds 
while binding with ERβ, which are also in the low toxicity class. Some 
literature showed that catechin and epicatechin have anti-resorptive 
properties and, hence, can increase osteoclast apoptosis and inhibit 
osteoclastogenesis. This is discovered by the ability of both 
compounds to inhibit the secretion of TNF-α and IL-6 in osteoblast 
cells. Decreased TNF-α and IL-6 resulted in increased bone mass and, 
decreased bone resorption.
43
 Furthermore, catechin and epicatechin 
can provide activity as well by ER-independent pathway mechanism. 
They can provide antioxidant activity by reducing NF-κB, TNF-α, 
nitric oxide (NO), and reactive oxygen species (ROS) activities. 
Because these cytokines induce oxidative stress, which leads to bone 
loss, reducing oxidative stress with antioxidants may be a possible 
strategy for osteoporosis prevention.
43,44
 Therefore, catechin and 
epicatechin can inhibit osteoporosis and may be developed into 
antiosteoporosis medicine for oral use.  
 
Conclusion 
Catechin and epicatechin are the most potent and non-toxic 
antiosteoporosis compounds among the 39 phytoestrogens that act 
through an ER-dependent mechanism. 
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